Tirzepatide Before and After: A Realistic Timeline

If you are searching for a tirzepatide before and after timeline, the most honest answer is that meaningful change unfolds over many months, not weeks. In the 72-week SURMOUNT-1 trial of adults with obesity or overweight (without type 2 diabetes), participants using tirzepatide with a reduced-calorie diet and increased physical activity lost an average of about 15.0% of body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg once weekly, compared with about 3.1% on placebo (treatment-regimen estimand, per the Zepbound FDA prescribing information). Those are averages from one trial, not a forecast for any individual. This article walks through what the data suggests about timing.

What does a realistic tirzepatide timeline look like?

Tirzepatide’s labeled dosing is deliberately slow. Per the Zepbound prescribing information, people start at 2.5 mg once weekly for four weeks, an initiation dose that is not intended to produce the full effect, then increase by 2.5 mg at intervals of at least four weeks toward a maintenance dose of 5, 10, or 15 mg (15 mg is the maximum). That means a person may not even reach a maintenance dose for two to five months.

Because the dose escalates gradually, the “before and after” story is rarely a sudden drop. In SURMOUNT-1, body-weight reduction accumulated steadily across the full 72 weeks rather than front-loading into the first month. Any week-by-week milestones you read online are estimates, not guarantees, and your own prescriber sets your schedule.

The table below summarizes the labeled escalation. It is educational only; your dose and pace are determined by a licensed provider, not by an article.

Phase	Weekly dose	Approximate timing
Initiation	2.5 mg	First 4 weeks (not a maintenance dose)
Step up	+2.5 mg increments	No sooner than every 4 weeks
Maintenance	5, 10, or 15 mg	Reached over roughly 2-5 months

For a deeper look at how these increments are typically sequenced, see our tirzepatide dosage chart. Tolerability also shapes the timeline, so it helps to understand tirzepatide side effects before you begin.

When might “before and after” changes start to show?

The published SURMOUNT-1 results report outcomes at fixed checkpoints rather than promising a specific week when a person will “notice” a difference. The pivotal data come from the Jastreboff et al. SURMOUNT-1 trial in NEJM (2022), a 72-week randomized study of 2,539 adults with obesity or overweight, excluding those with type 2 diabetes, comparing tirzepatide 5, 10, and 15 mg weekly against placebo with diet and activity.

Because the dose climbs slowly and weight loss accrued over the full study period, early weeks generally reflect dose initiation more than peak effect. The realistic framing: small, gradual changes are more typical early on, with larger average differences appearing later in the course, again as group averages rather than individual promises.

When does tirzepatide weight loss tend to plateau?

A plateau is expected, not a failure. An analysis of SURMOUNT trial data by Horn et al. in Clinical Obesity (2025) found that weight loss was progressive across the 72 weeks. Among tirzepatide-treated participants who were adherent and had achieved at least 5% weight loss by the primary endpoint, the median plateau was reached at roughly 24 to 36 weeks depending on baseline BMI, and about 88% to 90% had plateaued by week 72. That analysis describes this adherent-responder subset rather than every participant in the trial.

In plain terms: among those who responded, most of the average change happened across the better part of a year, and the curve tended to flatten in the second half. Reaching a plateau does not necessarily mean treatment has stopped working; it reflects the body settling at a new steady state. What happens next is a conversation for you and your prescriber.

How do the tirzepatide numbers compare with semaglutide?

People often compare these timelines. The two drugs were studied in separate trials with different populations and durations, so the figures are not directly interchangeable, but here is the head-to-head context from each drug’s own pivotal study.

Medication	Trial & duration	Mean weight change
Tirzepatide 5 / 10 / 15 mg	SURMOUNT-1, 72 wks	-15.0% / -19.5% / -20.9% vs -3.1% placebo
Semaglutide 2.4 mg	STEP 1, 68 wks	-14.9% vs -2.4% placebo

The semaglutide figure comes from the Wilding et al. STEP 1 trial in NEJM (2021), in which 1,961 adults with overweight or obesity (without diabetes) took semaglutide 2.4 mg weekly with lifestyle intervention for 68 weeks and lost about 14.9% on average versus about 2.4% on placebo. Both sets of figures assume a reduced-calorie diet and increased physical activity. For a fuller breakdown, see tirzepatide vs semaglutide. If you are weighing the two brand tirzepatide products, our Zepbound vs Mounjaro comparison covers how they differ.

Is the tirzepatide you see online FDA-approved?

This matters for anyone reading “before and after” content. Tirzepatide is the active ingredient in FDA-approved Zepbound and Mounjaro. Compounded tirzepatide is a different category: per the FDA’s guidance on unapproved GLP-1 drugs, compounded products are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they are marketed.

Availability has also changed. As national GLP-1 supply has stabilized, the FDA has clarified that routine large-scale compounding is no longer broadly permitted. The agency had earlier determined that the tirzepatide shortage was resolved (Declaratory Order, October 2024, reaffirmed December 2024), and that the semaglutide shortage was resolved (Declaratory Order, February 2025). Treatment decisions should be made with a licensed provider who can assess whether any therapy is appropriate for you.

Frequently asked questions

How much weight did people lose on tirzepatide in the trial?

In the 72-week SURMOUNT-1 trial of adults with obesity or overweight without type 2 diabetes, average body-weight reductions were about 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg weekly, versus about 3.1% on placebo, all with a reduced-calorie diet and increased physical activity. These are averages, and individual results vary.

How long until I reach the full dose?

The Zepbound label starts at 2.5 mg weekly for four weeks, then increases by 2.5 mg at intervals of at least four weeks toward a 5, 10, or 15 mg maintenance dose. That means roughly two to five months to reach a maintenance dose, but your prescriber determines your exact schedule.

When does tirzepatide weight loss plateau?

A SURMOUNT analysis (Horn et al., 2025) found weight loss was progressive over 72 weeks. Among adherent tirzepatide-treated participants who reached at least 5% weight loss, the median plateau was reached around 24 to 36 weeks by baseline BMI, and most had plateaued by week 72. A plateau is expected and is not necessarily a sign treatment has stopped working.

Is tirzepatide better than semaglutide?

They were tested in separate trials, so direct comparison is limited. In SURMOUNT-1, tirzepatide averaged up to about 20.9% reduction at 15 mg; in STEP 1, semaglutide 2.4 mg averaged about 14.9% (both figures are trial averages achieved with a reduced-calorie diet and increased physical activity, and individual results vary widely). Which is appropriate for you is a clinical decision for a licensed provider.

Is compounded tirzepatide FDA-approved?

No. Brand tirzepatide (Zepbound, Mounjaro) is FDA-approved, but compounded tirzepatide is not, and the FDA has not evaluated it for safety, quality, or effectiveness. Discuss any GLP-1 therapy with a licensed provider.

Will my before and after look like the trial photos online?

Not necessarily. Published figures are group averages from controlled trials paired with diet and exercise. Real-world outcomes depend on dose, adherence, starting weight, and many individual factors, so results vary considerably from person to person.